Lifyorli Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer: What Patients Should Know

Ovarian cancer that comes back after initial treatment can be challenging to manage, especially for patients who have already tried multiple therapies. A new combination of Lifyorli and weekly nab-paclitaxel is showing promise in helping patients control disease progression and potentially extend survival. We spoke with Dr. Robert Coleman about what this treatment means for patients, how it works, and what to consider when discussing it with a care team.

Cure: How does adding Lifyorli to nab-paclitaxel change what patients can expect in terms of survival and day-to-day quality of life?

Dr. Coleman: For patients with recurrent ovarian cancer, the main benefit of adding Lifyorli to nab-paclitaxel is controlling disease progression. Most patients move from one therapy to the next, so keeping the cancer from growing while minimizing side effects is the primary goal.

The combination extends the time patients remain on treatment without progression. Unlike many combinations that increase toxicity without improving outcomes, Lifyorli added to an effective chemotherapy backbone prolongs progression-free periods while maintaining tolerable side effects, supporting patients’ ability to carry out daily activities.

For patients who have already received multiple treatments, what makes Lifyorli plus nab-paclitaxel a meaningful new option?

Patients who have undergone multiple prior treatments often show disease progression at the next scan. Lifyorli plus nab-paclitaxel extends progression-free survival and has shown almost unprecedented improvements in overall survival. Even patients heavily pretreated now have a treatment option that meaningfully delays progression and improves the chance of longer-term benefit.

Since the ROSELLA trial did not require biomarker testing, how does that affect which patients may be able to receive Lifyorli?

Because the trial did not require a biomarker, most patients eligible for weekly nab-paclitaxel could potentially receive Lifyorli. Some factors, such as prior reactions to paclitaxel or pre-existing neuropathy, could limit eligibility. Patients previously treated with weekly paclitaxel were not included in the trial, so its effectiveness in that group remains unknown.

What should patients know about potential side effects when taking Lifyorli with nab-paclitaxel and how are they typically managed?

The side effects are generally consistent with what is expected from nab-paclitaxel alone. Combination therapy shows slightly higher rates of mild blood-related toxicities, such as low white or red blood cell counts, as well as gastrointestinal issues like nausea, vomiting, and diarrhea.

These side effects often reflect longer exposure to treatment and are usually manageable with routine monitoring and dose adjustments. Overall, the combination does not substantially increase severe toxicity compared with chemotherapy alone.

Can you explain in simple terms how Lifyorli works and why targeting the glucocorticoid receptor may help in platinum-resistant disease?

Lifyorli works by blocking the glucocorticoid receptor, which can protect cancer cells from chemotherapy-induced cell death. While glucocorticoids reduce inflammation and side effects, they can also blunt the effectiveness of chemotherapy by interfering with the cell death process.

By interrupting this pathway, Lifyorli allows chemotherapy to work more effectively. Nab-paclitaxel is an ideal partner because it can be given weekly without steroids, avoiding interference with treatment efficacy. This combination removes a mechanism of resistance and enhances the impact of chemotherapy in platinum-resistant disease.

What should patients discuss with their care team when deciding whether Lifyorli plus nab-paclitaxel is the right option for them?

Patients should discuss the benefits of weekly nab-paclitaxel and whether adding Lifyorli could help extend the time without disease progression. The combination has a favorable side-effect profile and is one of the few treatments in this setting to show an overall survival benefit, reducing the probability of death by about 30%. Patients should consider how this therapy fits with their treatment goals, previous therapies, and overall quality of life.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.